Elixira:
A Regulatory Feasibility Study and Strategic Blueprint for Nanoism

Requirements for Clinical Trials

Product: Elixira — an AI-guided, self-powered nanobot platform designed for lifelong cancer prevention, serving as the reference model for future Nanoism technologies.
Scope: Regulatory frameworks and clinical pathways for Elixira and Nanoism (preventive nanomedicine) under EU MDR 2017/745 and US FDA 21 CFR.
Author: Tess Fries
Affiliation: Inventor and Founder of Elixira; Founder of Nanoism
Contact: contact@elixira.tech
Date: September 2025
DOI: https://doi.org/10.5281/zenodo.17177676

Abstract

This regulatory feasibility study evaluates the anticipated classification, applicable standards, and requirements for initiating clinical trials of Elixira — an AI-guided, self-powered nanobot platform for lifelong cancer prevention. Covering both the European Union (EU MDR 2017/745) and the United States (FDA 21 CFR pathways), the study provides a CRO-level overview of regulatory considerations while preserving proprietary details.

This paper establishes the first regulatory feasibility pathway ever outlined for Nanoism — a medical discipline defined as lifelong preventive nanomedicine — and positions Elixira as its reference model. It specifies Class III designation in both regions, maps relevant ISO/IEC standards, and details preclinical testing requirements including biocompatibility, electrical safety, electromagnetic compatibility, and AI validation.

The study further demonstrates how accelerated regulatory pathways (EU MDR Article 59 derogations and the FDA Breakthrough Devices Program) can reduce the timeline from 3–5 years to approximately 1–2 years, with early ethical access provided to terminal patients under established Compassionate Use protocols. An estimated regulatory timeline is presented alongside key risks and mitigation strategies. The study concludes with recommended next steps for engaging regulatory authorities, ensuring harmonized documentation, and de-risking the transition from preclinical evaluation to first-in-human trials while ensuring patient safety at every stage.

Keywords:
Elixira, Nanoism, Tess Fries, Nanomedicine, Nanotechnology, Cancer Prevention, Preventive Medicine, Regulatory Feasibility, EU MDR 2017/745, FDA 21 CFR, Class III Medical Device, AI-Guided Nanobot, Compassionate Use Protocol, Compassionate Protocol, Ethical Access, Clinical Trials, Fast-Track, PMA, Preclinical Testing, ISO 10993, IEC 60601, CE Marking, Accelerated Approval, Translational Medicine

1. Introduction

This regulatory feasibility study outlines the anticipated classification, applicable standards, and detailed requirements for initiating clinical trials for Elixira in both the European Union and the United States. It includes an estimated regulatory timeline, identified risks with mitigation strategies, and example preclinical testing protocols to provide a CRO-level view while preserving proprietary details.

2. Regulatory Classification

Region	Framework	Anticipated Classification	Justification
EU	MDR 2017/745, Annex VIII, Rules 8 & 9	Class III, Active Implantable Medical Device	Permanently implantable, electrically active, life-sustaining therapeutic function
US	21 CFR Part 860	Class III (PMA)	Implantable, high-risk medical device with novel technology

3. Applicable Standards and Guidance

Category	Reference	Relevance
Quality Management	ISO 13485	QMS for medical device manufacturing
Risk Management	ISO 14971	Mandatory for device risk analysis
Biocompatibility	ISO 10993 series	Safety evaluation of materials in contact with tissue/blood
Electrical Safety	IEC 60601-1	Active implantable device safety
EMC	IEC 60601-1-2	Electromagnetic compatibility
Software Lifecycle	IEC 62304	Medical software development, including AI components
AI/ML	FDA AI/ML Action Plan; MDR AI guidance (upcoming)	AI-specific validation and monitoring
Nanotechnology	ISO/TR 10993-22; FDA Nanotechnology Guidance	Nanostructure toxicology and safety

4. Preclinical Requirements

Shared EU & US requirements include: in vitro testing (cytotoxicity, genotoxicity, immunogenicity), in vivo biocompatibility studies per ISO 10993-1, bench testing for mechanical, electrical, and functional performance, AI decision-making accuracy verification, and electromagnetic compatibility testing.

5. Estimated Regulatory Timeline

Phase	EU MDR	US FDA	Estimated Duration
Regulatory Consultation	Notified Body pre-classification	FDA Q-Submission	1-3 months
Preclinical Testing	ISO 10993 series, IEC 60601, AI validation	Biocompatibility, bench & EMC tests	6-12 months
Ethics & Authority Approvals	Ethics Committee + Competent Authority	IRB + IDE approval	3-6 months
Clinical Investigation	Annex XV GCP-compliant	IDE GCP-compliant	12-24 months
Market Authorization	CE Marking	PMA Approval	6-12 months

6. Regulatory Risks and Mitigation

Risk	Impact	Mitigation
AI adaptivity questioned by regulators	Approval delays	Initial launch with locked AI algorithm
Nanomaterial long-term safety	Additional studies required	Early biodistribution & clearance testing
Energy harvesting EMC interference	Safety concerns	Independent EMC certification pre-clinical
Combination product classification	Dual regulatory oversight	Initial filing as pure device

6a. Accelerated Pathways for Life-Saving Devices

Given Elixira's classification as a Class III active implantable medical device, both EU MDR and FDA provide mechanisms to accelerate access for life-saving technologies. These accelerated mechanisms are designed to reduce regulatory delays without compromising safety or scientific integrity.

- **European Union (MDR):** Article 59 of MDR allows derogations in the interest of public health, enabling earlier patient access. Compassionate use programs will be implemented where no alternatives exist. Certain Notified Bodies will prioritize breakthrough devices.

- **United States (FDA):** The Breakthrough Devices Program provides prioritized review, early interactions, and potential expedited approval for technologies addressing life-threatening conditions with no adequate alternatives. Expanded Access (Compassionate Use) further allows early patient access prior to full approval.

By leveraging these pathways, Elixira will shorten the time from preclinical validation to first-in-human studies, potentially reducing a standard 3–5 year regulatory process to approximately 1–2 years, contingent on CRO execution and funding.

6b. Global Outlook

Beyond the EU and US, other major regulatory agencies are also advancing expedited frameworks for life-saving devices. Japan's PMDA, the UK's MHRA, and Health Canada all operate priority review and compassionate access pathways, enabling earlier adoption of breakthrough technologies.
These pathways will be actively implemented to ensure Elixira achieves globally accelerated deployment.

6c. Additional Accelerated Pathways (Safety-Preserved)

Beyond Article 59 derogations in the EU and the FDA Breakthrough Devices and Expanded Access programs, further mechanisms exist to ethically shorten regulatory timelines while maintaining patient safety.

- Adaptive Trial Designs (FDA/EMA): Regulators allow innovative trial designs that combine or overlap phases (e.g., Phase I/II or II/III), reducing time while ensuring robust safety and efficacy data are collected.

- Emergency Use Authorization (FDA): In the context of a declared public health crisis, such as the global burden of cancer, FDA can grant temporary market access for devices addressing urgent unmet needs.

- Humanitarian Device Exemption (HDE, FDA): Provides a pathway for devices intended to treat or diagnose rare, life-threatening conditions, allowing limited market entry with reduced evidence requirements.

- Parallel Scientific Advice (EMA + Notified Body): Joint consultations enable simultaneous regulatory and notified body feedback, streamlining classification and approval for potential combination products.

By strategically leveraging these additional pathways, Elixira and future Nanoism technologies can further minimize regulatory delays while ensuring that every accelerated process remains anchored in rigorous scientific standards where safety comes first.

7. Example Preclinical Test Protocols (Indicative)

To ensure uncompromised patient safety, the following preclinical protocols are designed to validate core risk domains prior to human exposure:

Biocompatibility: ISO 10993-1 chronic implantation study in appropriate animal model with histopathology assessment at 1, 3, and 6 months.

Electrical Safety: IEC 60601-1 compliance testing including leakage current, dielectric strength, and mechanical integrity.

AI Validation: Closed-set performance testing with >95% sensitivity and specificity for malignant cell identification, validated against gold-standard histology.

EMC Testing: IEC 60601-1-2 electromagnetic immunity and emissions testing under simulated physiological conditions.

8. Recommendations – Next Steps

EU: Arrange classification meeting with Notified Body, initiate ISO 10993 material testing, draft Clinical Investigation Plan. US: Submit Q-Sub to FDA, prepare IDE, finalize locked AI model for PMA.
Global: Maintain harmonized Technical File and only engage full-service regulatory advisors at the preclinical-to-clinical transition to minimize cost. Ethical deployment will be implemented, including compassionate use pathways to provide access for terminal patients where no adequate alternatives exist.

This feasibility study is a non-binding assessment based on current regulatory frameworks and public guidance. Final classification and requirements must be confirmed through engagement with the relevant authorities.

9. Licensing and Translational Relevance

While this feasibility study is focused on Elixira, the same regulatory considerations apply to forthcoming Nanoism technologies — preventive nanomedicine platforms designed for lifelong patient benefit.

For licensees, key translational factors include:

- Patent protection and Freedom to Operate (FTO): Ensuring secure intellectual property positions across jurisdictions.
- Harmonized regulatory dossier: Enabling streamlined adoption across EU, US, and global markets without duplication of effort.
- Scalability and manufacturing readiness: Pathways to industrial production with CRO/CDMO partners.
- Reimbursement potential: Early access through compassionate use frameworks and long-term integration into public health systems.
- Ethical and societal positioning: Highlighting Nanoism technologies as life-saving and preventive innovations where patient safety remains paramount.

These elements ensure that Elixira, and the broader Nanoism discipline, can be translated rapidly and responsibly from regulatory approval to global patient access highlighting Nanoism technologies as life-saving and preventive innovations where rapid access and uncompromised safety remain guiding principles.

Conclusion

This regulatory feasibility study demonstrates that Elixira — as the reference model for Nanoism — is technically and regulatorily feasible under existing EU MDR and FDA Class III frameworks. By leveraging accelerated pathways, including Article 59 derogations and the FDA Breakthrough Devices Program, Nanoism can transition from preclinical validation to first-in-human trials within 1–2 years. Beyond Elixira, this blueprint establishes Nanoism as the foundation of a new era in global preventive medicine, enabling lifelong cancer prevention and setting the stage for broader applications in human health.

Author’s Note

This study was authored by Tess Fries, inventor and founder of Elixira and originator of Nanoism, with the intention of accelerating lifelong, lifesaving disease prevention platforms within this new medical discipline. It is written not only as a regulatory feasibility assessment, but also as a guide toward a future where disease is prevented before it can take hold. The work represents a landmark contribution to drive accelerated global adoption of Nanoism, with safety, ethics, and human dignity at its core. This marks the first regulatory feasibility pathway ever outlined for Nanoism.

© 2025 Tess Fries. All rights reserved by the author.

References

European Parliament and of the Council. (2017). *Regulation (EU) 2017/745 on medical devices (MDR). Official Journal of the European Union.* https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A32017R0745

U.S. Food and Drug Administration. (2022). *Code of Federal Regulations, Title 21, Part 860 — Medical device classification procedures.* https://www.ecfr.gov/current/title-21/chapter-I/subchapter-H/part-860

U.S. Food and Drug Administration. (2023). *Breakthrough devices program.* https://www.fda.gov/medical-devices/how-study-and-market-your-device/breakthrough-devices-program

U.S. Food and Drug Administration. (2022). *Expanded access (Compassionate Use).* https://www.fda.gov/news-events/public-health-focus/expanded-access

International Organization for Standardization. (2016). *ISO 13485:2016 — Medical devices — Quality management systems — Requirements for regulatory purposes.* https://www.iso.org/standard/59752.html

International Organization for Standardization. (2019). *ISO 14971:2019 — Medical devices — Application of risk management to medical devices.* https://www.iso.org/standard/72704.html

International Organization for Standardization. (2018). *ISO 10993-1:2018 — Biological evaluation of medical devices — Part 1: Evaluation and testing within a risk management process.* https://www.iso.org/standard/68936.html

International Electrotechnical Commission. (2005/2012/2020). *IEC 60601-1:2005+A1:2012+A2:2020 — Medical electrical equipment — Part 1: General requirements for basic safety and essential performance.* https://webstore.iec.ch/publication/2612

International Electrotechnical Commission. (2014/2020). *IEC 60601-1-2:2014+A1:2020 — Medical electrical equipment — Part 1-2: … Electromagnetic disturbances — Requirements and tests.* https://webstore.iec.ch/en/publication/67554

International Electrotechnical Commission. (2006/2015). *IEC 62304:2006+AMD1:2015 (CSV) — Medical device software — Software life cycle processes.* https://webstore.iec.ch/en/publication/22794